Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler

Meliha Çağla SÖNMEZER, (Ankara Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara, Türkiye)
Necla TÜLEK (Ankara Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara, Türkiye)
Klimik Dergisi
5 1
Yıl: 2015 Cilt: 28 Sayı: 3 Sayfa Aralığı: 96 - 102 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler

Öz:
Sepsis, ciddi bakteriyel infeksiyona karşı sistemik yanıtın sonucu olarak ortaya çıkan ve yaşamı tehdit eden bir klinik durumdur. Tüm dünyada antibiyotik kullanımının ve destek tedavilerinin artmasına karşın sepsisin sıklığında bir azalma olmamıştır. İlk klinik bulgularının özgül olmamasından dolayı sepsisi daha erken dönemde tanımaya yönelik güncel arayışlardan birisini de biyobelirteçlerin kullanılması oluşturmaktadır. Bu derlemede bakteriyel infeksiyonlara bağlı olarak gelişen sepsisin tanısı için kullanılabilecek biyobelirteçler gözden geçirilmiştir. Klimik Dergisi 2015; 28(3): 96-102
Anahtar Kelime:

Konular: Mikrobiyoloji Enfeksiyon Hastalıkları

Biomarkers in Bacterial Infections and Sepsis

Öz:
Sepsis is a life threatening clinical condition which occurs as a result of systemic response to serious bacterial infection. Increase of antibiotic use and supportive therapy has not led to a decrease in the prevalence of sepsis in the world. Because early clinical signs of sepsis are not specific, researchers are looking for new ways to diagnose sepsis earlier using biomarkers. Potential biomarkers for diagnosis of sepsis caused by bacterial infections are reviewed. Klimik Dergisi 2015; 28(3): 96-102
Anahtar Kelime:

Konular: Mikrobiyoloji Enfeksiyon Hastalıkları
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Dupuy AM, Philippart F, Péan Y, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infec- tions. Ann Intensive Care. 2013; 3(1): 22.
  • Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for report- ing of diagnostic accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003; 138(1): W1-12. [CrossRef]
  • Bachmann LM, Jüni P, Reichenbach S, Ziswiler HR, Kessels AG, Vögelin E. Consequences of different diagnostic "gold stan- dards" in test accuracy research: Carpal Tunnel Syndrome as an example. Int J Epidemiol. 2005; 34(4): 953-5.
  • Bozza FA, Bozza PT, Castro Faria Neto HC. Beyond sepsis patho- physiology with cytokines: what is their value as biomarkers for disease severity? Mem Inst Oswaldo Cruz. 2005; 100(Suppl. 1): 217-21. [CrossRef]
  • Meisner M. Biomarkers of sepsis: clinically useful? Curr Opin Crit Care. 2005; 11(5): 473-80. [CrossRef]
  • Marshall JC, Vincent JL, Fink MP, et al. Measures, markers, and me- diators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med. 2003; 31(5): 1560-7. [CrossRef]
  • Cho SY, Choi HJ. Biomarkers of sepsis. Infect Chemother. 2014; 46(1): 1-12. [CrossRef]
  • Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010; 14(1): R15. [CrossRef]
  • Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomark- ers of sepsis in critical care. J Antimicrob Chemother. 2011; 66(Suppl. 2): ii33-40. [CrossRef]
  • Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum pro- calcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004; 39(2): 206-17. [CrossRef]
  • Póvoa P. C-reactive protein: a valuable marker of sepsis. Inten- sive Care Med. 2002; 28(3): 235-43. [CrossRef]
  • Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003; 111(12): 1805-12. [CrossRef]
  • Smith JW, Colombo JL, McDonald TL. Comparison of serum amy- loid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients. J Clin Lab Anal. 1992;6(4):219-24. [CrossRef]
  • Haris KR, Digard NJ, Lee HA. Serum C-reactive protein. A useful and economical marker of immune activation in renal transplan- tation. Transplantation. 1996; 61(11): 1593-600.
  • Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels cor- relate with mortality and organ failure in critically ill patients. Chest. 2003; 123(6): 2043-9. [CrossRef]
  • Póvoa P, Teixeira-Pinto AM, Carneiro AH; Portuguese Community- Acquired Sepsis Study Group SACiUCI. C-reactive protein, an early marker of community acquired sepsis resolution: A multicenter pro- spective observational study. Crit Care. 2011; 15(4): R169. [CrossRef]
  • Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Pro- calcitonin for early diagnosis and differentiation of SIRS, sep- sis, severe sepsis, and septic shock. Intensive Care Med. 2000; 26(Suppl. 2): S148-52. [CrossRef]
  • Reith HB, Mittelkötter U, Wagner R, Thiede A. Procalcitonin (PCT) in patients with abdominal sepsis. Intensive Care Med. 2000; 26(Suppl. 2): S165-9. [CrossRef]
  • Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin In- fect Dis. 2002; 34(7): 895-901. [CrossRef]
  • Panico C, Nylen E. Procalcitonin beyond the acute phase: novel biomediator properties? BMC Med. 2013;11: 189. [CrossRef]
  • Rothenburger M, Markewitz A, Lenz T, et al. Detection of acute phase response and infection. The role of procalcitonin and C-reac- tive protein. Clin Chem Lab Med. 1999; 37(3): 275-9. [CrossRef]
  • Gendrel D, Raymond J, Assicot M, et al. Measurement of procal- citonin levels in children with bacterial or viral meningitis. Clin Infect Dis. 1997; 24(6): 1240-2. [CrossRef]
  • Konstantinidis T, Cassimos D, Gioka T, et al. Can procalcitonin in cerebrospinal fluid be a diagnostic tool for meningitis? J Clin Lab Anal. 2015; 29(3): 169-74. [CrossRef]
  • Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta- analysis. Lancet Infect Dis. 2013; 13(5): 426-35. [CrossRef]
  • Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalci- tonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009; 302(10): 1059-66. [CrossRef]
  • Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneu- monia. Crit Care. 2010; 14(1): 203. [CrossRef]
  • Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol. 2007; 297(5): 353-63. [CrossRef]
  • Oude Nijhuis CS, Vellenga E, Daenen SM, et al. Lipopolysaccha- ride-binding protein: a possible diagnostic marker for Gram- negative bacteremia in neutropenic cancer patients. Intensive Care Med. 2003; 29(12): 2157-61. [CrossRef]
  • Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospec- tive study. Crit Care. 2006;10(2):R53. [CrossRef]
  • Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Ath- erothrombosis. Inflammation in atherosclerosis: from pathophysiol- ogy to practice. J Am Coll Cardiol. 2009; 54(23): 2129-38. [CrossRef]
  • Kao SJ, Yang HW, Tsao SM, et al. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med. 2013; 51(4): 907-13. [CrossRef]
  • Lin Q, Fu F, Shen L, Zhu B. Pentraxin 3 in the assessment of ventilator-associated pneumonia: an early marker of severity. Heart Lung. 2013; 42(2): 139-45. [CrossRef]
  • Andaluz-Ojeda D, Bobillo F, Iglesias V, et al. A combined score of pro- and anti-inflammatory interleukins improves mortality pre- diction in severe sepsis. Cytokine. 2012; 57(3): 332-6. [CrossRef]
  • Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013; 50(1): 23-36. [CrossRef]
  • Lvovschi V, Arnaud L, Parizot C, et al. Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study. PLoS One. 2011; 6(12): e28870. [CrossRef]
  • Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001; 164(3): 396-402. [CrossRef]
  • Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cyto- kine. 2005; 29(4): 169-75. [CrossRef]
  • Kleine TO, Zwerenz P, Zöfel P, Shiratori K. New and old diagnos- tic markers of meningitis in cerebrospinal fluid (CSF). Brain Res Bull. 2003; 61(3): 287-97. [CrossRef]
  • Ramírez P, Ferrer M, Gimeno R, et al. Systemic inflammatory re- sponse and increased risk for ventilator-associated pneumonia: a preliminary study. Crit Care Med. 2009; 37(5): 1691-5. [CrossRef]
  • Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventila- tor-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother. 2012; 56(7): 3819-25.
  • de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by mono- cytes. J Exp Med. 1991; 174(5): 1209-20. [CrossRef]
  • Kellum JA, Kong L, Fink MP, et al. GenIMS Investigators. Understand- ing the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007; 167(15): 1655-63.
  • Angus DC, Yang L, Kong L, et al. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncompli- cated pneumonia and pneumonia with severe sepsis. Crit Care Med. 2007; 35(4): 1061-7. [CrossRef]
  • Gibot S, Massin F, Cravoisy A, et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med. 2007; 33(8): 1347-53. [CrossRef]
  • Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000; 21(2): 138-67.
  • Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004; 25(8): 1369-72. [CrossRef]
  • Angeletti S, Battistoni F, Fioravanti M, Bernardini S, Dicuonzo G. Procalcitonin and mid-regional pro-adrenomedullin test com- bination in sepsis diagnosis. Clin Chem Lab Med. 2013; 51(5): 1059-67. [CrossRef]
  • Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedul- lin to predict severity and outcome in community-acquired pneu- monia [ISRCTN04176397]. Crit Care. 2006; 10(3): R96 [CrossRef]
  • Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflam- matory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010; 182(11): 1426-34. [CrossRef]
  • Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vaso- pressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007; 28(2): 219-26. [CrossRef]
  • Barat C, Simpson L, Breslow E. Properties of human vasopres- sin precursor constructs: inefficient monomer folding in the ab- sence of copeptin as a potential contributor to diabetes insipi- dus. Biochemistry. 2004; 43(25): 8191-203. [CrossRef]
  • Krüger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med. 2007; 33(12): 2069-78. [CrossRef]
  • Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teix- eira PJ. Copeptin, a novel prognostic biomarker in ventilator- associated pneumonia. Crit Care. 2008; 12(1): R11. [CrossRef]
  • Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J. 2004; 25(14): 1187-96. [CrossRef]
  • Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care. 2005; 9(1): R37-45. [CrossRef]
  • Shah R. Endothelins in health and disease. Eur J Intern Med. 2007; 18(4): 272-82. [CrossRef]
  • Tschaikowsky K, Sägner S, Lehnert N, Kaul M, Ritter J. Endothe- lin in septic patients: effects on cardiovascular and renal func- tion and its relationship to proinflammatory cytokines. Crit Care Med. 2000; 28(6): 1854-60. [CrossRef]
  • Schuetz P, Stolz D, Mueller B, et al. Endothelin-1 precursor pep- tides correlate with severity of disease and outcome in pa- tients with community acquired pneumonia. BMC Infect Dis. 2008; 8: 22. [CrossRef]
  • Schuetz P, Christ-Crain M, Zimmerli W, Mueller B. Repeated mea- surements of endothelin-1 precursor peptides predict the out- come in community-acquired pneumonia. Intensive Care Med. 2011; 37(6): 970-80. [CrossRef]
  • Millner MM, Franthal W, Thalhammer GH, et al. Neopterin con- centrations in cerebrospinal fluid and serum as an aid in dif- ferentiating central nervous system and peripheral infections in children. Clin Chem. 1998; 44(1): 161-7.
  • Kozlowska-Murawska J, Obuchowicz AK. Clinical usefulness of neopterin. Wiad Lek. 2008; 61(10-12): 269-72.
  • Ruokonen E, Ilkka L, Niskanen M, Takala J. Procalcitonin and ne- opterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand. 2002; 46(4): 398-404. [CrossRef]
  • Aziz N, Nishanian P, Taylor JM, et al. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. J Infect Dis. 1999; 179(4): 843-8. [CrossRef]
  • Stein DS, Lyles RH, Graham NM, et al. Predicting clinical pro- gression or death in subjects with early-stage human immu- nodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. J Infect Dis. 1997; 176(5): 1161-7. [CrossRef]
  • Ng PC, Lam HS. Diagnostic markers for neonatal sepsis. Curr Opin Pediatr. 2006; 18(2): 125-31. [CrossRef]
  • Arnon S, Litmanovitz I. Diagnostic tests in neonatal sepsis. Curr Opin Infect Dis. 2008; 21(3): 223-7. [CrossRef]
  • Cid J, Aguinaco R, Sánchez R, García-Pardo G, Llorente A. Neu- trophil CD64 expression as marker of bacterial infection: a sys- tematic review and meta-analysis. J Infect. 2010; 60(5): 313-9. [CrossRef]
  • Gros A, Roussel M, Sauvadet E, et al. The sensitivity of neutro- phil CD64 expression as a biomarker of bacterial infection is low in critically ill patients. Intensive Care Med. 2012; 38(3): 445-52. [CrossRef]
  • Icardi M, Erickson Y, Kilborn S, Stewart B, Grief B, Scharnweber G. CD64 index provides simple and predictive testing for detec- tion and monitoring of sepsis and bacterial infection in hospital patients. J Clin Microbiol. 2009; 47(12): 3914-9. [CrossRef]
  • Phua J, Koay ES, Zhang D, et al. Soluble triggering receptor ex- pressed on myeloid cells-1 in acute respiratory infections. Eur Respir J. 2006; 28(4): 695-702. [CrossRef]
  • Gibot S, Cravoisy A. Soluble form of the triggering receptor ex- pressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res. 2004; 2(3): 181-7. [CrossRef]
  • Gibot S, Kolopp-Sarda MN, Béné MC, et al. Plasma level of a trig- gering receptor expressed on myeloid cells-1: its diagnostic ac- curacy in patients with suspected sepsis. Ann Intern Med. 2004; 141(1): 9-15. [CrossRef]
  • Tejera A, Santolaria F, Diez ML, et al. Prognosis of community ac- quired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflam- matory response. Cytokine. 2007; 38(3): 117-23.
  • Träger K, Radermacher P, Leverve X. The adrenergic coin: perfu- sion and metabolism. Intensive Care Med. 2003; 29(2): 150-3.
  • Trzeciak S, Dellinger RP, Chansky ME, et al. Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med. 2007; 33(6): 970-7. [CrossRef]
  • Viallon A, Desseigne N, Marjollet O, et al. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis. Crit Care. 2011; 15(3): R136.[CrossRef]
  • Xiao B, Liu Z, Li BS, et al. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J Infect Dis. 2009; 200(6): 916-25. [CrossRef]
  • Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013; 253(1): 146-57. [CrossRef]
  • Vasilescu C, Rossi S, Shimizu M, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One. 2009; 4(10): e7405. [CrossRef]
APA SÖNMEZER M, Tulek N (2015). Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. , 96 - 102.
Chicago SÖNMEZER Meliha Çağla,Tulek Necla Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. (2015): 96 - 102.
MLA SÖNMEZER Meliha Çağla,Tulek Necla Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. , 2015, ss.96 - 102.
AMA SÖNMEZER M,Tulek N Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. . 2015; 96 - 102.
Vancouver SÖNMEZER M,Tulek N Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. . 2015; 96 - 102.
IEEE SÖNMEZER M,Tulek N "Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler." , ss.96 - 102, 2015.
ISNAD SÖNMEZER, Meliha Çağla - Tulek, Necla. "Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler". (2015), 96-102.
APA SÖNMEZER M, Tulek N (2015). Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. Klimik Dergisi, 28(3), 96 - 102.
Chicago SÖNMEZER Meliha Çağla,Tulek Necla Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. Klimik Dergisi 28, no.3 (2015): 96 - 102.
MLA SÖNMEZER Meliha Çağla,Tulek Necla Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. Klimik Dergisi, vol.28, no.3, 2015, ss.96 - 102.
AMA SÖNMEZER M,Tulek N Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. Klimik Dergisi. 2015; 28(3): 96 - 102.
Vancouver SÖNMEZER M,Tulek N Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler. Klimik Dergisi. 2015; 28(3): 96 - 102.
IEEE SÖNMEZER M,Tulek N "Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler." Klimik Dergisi, 28, ss.96 - 102, 2015.
ISNAD SÖNMEZER, Meliha Çağla - Tulek, Necla. "Bakteriyel İnfeksiyonlarda ve Sepsiste Biyobelirteçler". Klimik Dergisi 28/3 (2015), 96-102.
Sayfa Oluşturulma Tarihi
22-04-2024 23:12

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları